Health · 1 views

FDA approves Welireg with pembrolizumab for renal cell carcinoma

The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and be…

Source Medical Xpress AI Summary Updated 3h 19m ago

Story intelligence Beta

Freshness Fresh Updated 3h 19m ago

Confidence Limited Single-outlet story

Coverage Single outlet

Views 1 Community interest

Read time 1 min ~54 words

AI Summary

The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear cell component at intermediate-high or high risk for recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Read full article on Medicalxpress

AI summaries can be wrong sometimes—always verify important details using the source article.